Position: Postdoc Position in Preclinical Research
Department: Pediatric Neurooncology at DKFZ and KiTZ
Code number: 2024-0174
The German Cancer Research Center is the largest biomedical research institution in Germany. With more than 3,000 employees, we operate an extensive scientific program in the field of cancer research.
Survival rates for children with solid tumours, including brain tumours, have largely stagnated over the past 30 years. Although the unique biology of childhood solid tumours offers distinct vulnerabilities, many oncogenic driver events were previously considered ‘undruggable’. With advances in targeted protein degradation and chemical interventions to inhibit protein-protein interactions, it has recently become feasible to target such oncogenes, providing the basis for novel innovative interventions.
The project "PROTECT" (Harnessing protein degradation for advanced childhood tumours) involves 9 research institutions around the globe and is part of the Cancer Grand Challenge, funded by the Cancer Research UK, the National Cancer Institute, the Scientific Foundation of the Spanish Association Against Cancer and KiKa (Children Cancer Free Foundation) providing more than 25 million dollars over five years. To fuel the next wave of improvements in childhood cancer outcomes, the consortium aims at utilizing innovative compounds such as protein degraders and molecular glues to target unique drivers of childhood cancers. These comprise, but are not limited to, genetic fusion events that act as key drives across various different paediatric cancer entities and therefore pose ideal targets of high, unmet clinical need.
The applicant will accompany the development of multiple compounds at various stages of development and team up with experts in medicinal chemistry, cancer biology, paediatric preclinical research, and clinical trials. As a last step of this pipeline, the advertised project focusses on prioritizing most promising compounds to conduct preclinical validation both in house and through our collaboration partner ITCC-P4 (www.itccp4.com). To this end, the applicant will be able to leverage an existing array of in vivo models to evaluate dosing, scheduling, toxicity, and potential combination therapies.
For more info:
https://www.kitz-heidelberg.de/en/the-kitz/kitz-newsroom/kitz-news/detail/25-million-of-funding-for-new-cancer-treatments-for-children
https://www.kitz-heidelberg.de/en/research/research-groups/cns-/-brain-tumors/group-preclinical-modeling
https://cancergrandchallenges.org/teams/protect
www.itccp4.com